drugset / Trial / NCT07098780

Role of Tranexamic Acid in Reducing Hemorrhagic Events in Bariatric Surgery

NCT07098780 ↗

Phase 4 Recruiting 140 enrolled Patel Hospital, Pakistan
RandomizedParallel-groupTriple-blindTreatment

Summary

The goal of this clinical trial is to learn if tranexamic acid (TXA) helps reduce bleeding during bariatric surgery, such as laparoscopic sleeve gastrectomy (LSG) and mini gastric bypass (MGB). It will also look at how safe TXA is for people undergoing these procedures. The main questions it aims to answer are: Does TXA reduce the amount of blood loss during bariatric surgery? Are there any side effects or complications in patients who receive TXA? Researchers will compare TXA to standard care (no TXA) to see if it is effective in reducing bleeding. Participants will: Receive either TXA or no TXA (placebo) before surgery Undergo standard bariatric surgery (LSG or MGB) Have their blood loss, hemoglobin levels, and any complications monitored during and after surgery

Timeline

Start
2023-06-12
Primary completion
2025-07-31
Completion
2025-08-31

Outcome

Met primary endpoint

paper The treatment group receiving tranexemic acid, required significantly less number of haemostatic stitches for staple line bleeding (19 vs 46, p < 0.05) PMID 26694209 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Tranexamic Acid Small molecule 1000 mg Intravenous